Project Grant R43EY038159
Award Date 9/30/25
Completion Date 9/29/26
Dollars Obligated $305K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Palo Alto, CA 94306, USA
Similar Awards
- The National Eye Institute (NEI), under the federal Vision Research grant program (CFDA 93.867), awarded a $300,016 project grant to Fannin Partners LLC, a Houston-based biomedical research company, to develop SCG3 raptamers as a novel targeted therapy for wet age-related macular degeneration (AMD). Wet AMD is a leading cause of vision loss, affecting over 1.25 million individuals in the United States. The project aims to create an aptamer-based treatment that targets secretogranin III (SCG3), a...
- This $440,000 Project Grant award from the National Eye Institute (NEI), under Federal Grant Program 93.867 (Vision Research), aims to develop a novel, disease-targeted anti-angiogenic therapy for treating wet age-related macular degeneration (AMD). The key product being developed is a neutralizing monoclonal antibody that targets a new, CNV-selective angiogenic factor discovered through the awardee's comparative ligandomics technology. This approach differs from currently approved anti-VEGF...
- This Project Grant award of $310,952 from the National Eye Institute's Vision Research program, awarded on August 1, 2025, supports the development of a novel gene therapy approach by Bedrock Therapeutics, Inc., a small disadvantaged biotech company located in Raleigh, North Carolina. The goal is to create an effective and practical treatment for neovascular age-related macular degeneration (NAMD), the leading cause of blindness in people over 50. Bedrock's strategy combines an...
- The National Eye Institute (NEI) awarded a $312,239 Project Grant under the Vision Research federal grant program (CFDA 93.867) to Shift Pharmaceuticals Holdings, Inc. for the development of an antisense oligonucleotide (ASO) therapeutic to inhibit retinoic acid signaling and mitigate vision loss in retinitis pigmentosa and age-related macular degeneration. The project aims to create a targeted ASO therapy that can block the production of retinoic acid receptors at the cellular level within...
- The National Eye Institute (NEI), under the Department of Health and Human Services, awarded a $358,065 Project Grant to Revel Pharmaceuticals Inc., a biotechnology company in San Francisco, California. The grant is part of the NEI's Vision Research program (CFDA 93.867), which supports research to understand, prevent, and treat vision-related conditions and diseases. The goal of this Phase I grant is for Revel Pharmaceuticals to optimize lead drug candidates and demonstrate the activity of...
- This $1,813,621 Project Grant was awarded by the National Eye Institute (NEI) under the Vision Research federal grant program (CFDA 93.867) to support a research project titled "Nutritional Metabolomics in Age-Related Macular Degeneration and Retinal Integrity". The grant, awarded to The Research Foundation For The State University Of New York (RF SUNY), will fund the analysis of approximately 2,000 metabolites from participant serum samples to examine the relationship between...
- This $257,785 Project Grant was awarded on April 1, 2025 by the National Eye Institute (NEI) under the Vision Research federal grant program (CFDA 93.867). The grant supports the development of a refillable micromachined lens capsule-based drug delivery device for extended intraocular delivery of biologics and immune-modulating peptides to treat non-infectious uveitis. The key products/services to be delivered under this 4-year grant include: Characterizing and controlling the release of the...
- This $638,625 Project Grant awarded by the National Eye Institute (CFDA 93.867 - Vision Research) to the University of California, San Diego (UC San Diego) aims to investigate the mechanism of drusen formation in age-related macular degeneration (AMD). The research will utilize a novel Bruch's membrane-on-a-chip assay developed by the university to study the retention of lipoproteins in the extracellular matrix, which is believed to contribute to drusen accumulation in the early and intermediate...
- This $244,379 Project Grant award from the National Eye Institute's Vision Research program (CFDA 93.867) supports research at the University of California, Los Angeles (UCLA) to explore how genetic variation influences disease progression and treatment response in age-related macular degeneration (AMD), a leading cause of vision loss. The project aims to leverage machine learning (ML) and artificial intelligence (AI) techniques to analyze optical coherence tomography (OCT) imaging data and...
- This Project Grant award of $253,500.00 from the National Eye Institute (CFDA 93.867 - Vision Research) supports research by the Icahn School of Medicine at Mount Sinai to reconstruct a human blood-retina barrier and perfused vascular system. The goal is to investigate the role of apolipoprotein E (APOE) variants in age-related macular degeneration (AMD), a leading cause of vision loss. The researchers will optimize an in vitro human outer blood-retina barrier model to study AMD phenotypes and...